Event Details
Circa 2015
Description
The FDA clearing the drug Praluent for patients with heterozygous familial hypercholesterolemia and certain types of heart disease.
Participants (2)
| Name | Type | Mentions | |
|---|---|---|---|
| FDA | person | 0 | View Entity |
| Regeneron | organization | 22 | View Entity |
Source Documents (1)
HOUSE_OVERSIGHT_026363.jpg
This document is a printout of an article, likely from Forbes circa 2015, discussing a new cholesterol drug, Praluent. The article details the drug's effectiveness, its high cost ($14,600/year), and the companies involved, such as Regeneron, Sanofi, and Amgen. Although the document has a 'HOUSE_OVERSIGHT' Bates number, its content does not contain any explicit mention of Jeffrey Epstein or related individuals, and its relevance to that case is not apparent from the text itself.
Related Events
Events with shared participants
Investor Relations Conference Call hosted by Sanofi and Regeneron to discuss Praluent.
2015-07-24 • Teleconference / Webcast
Investor Relations Conference Call on Praluent for the financial community.
2015-07-24 • Teleconference / Webcast
FDA convened a meeting to analyze data on the drug Praluent, leading to its approval for a larger group of patients than expected.
Date unknown • U.S.
Trading of Regeneron shares was halted pending news.
Date unknown
FDA approval of Marinol and Cesamet
1985-01-01 • USA
Marinol approved for treatment of anorexia associated with AIDS
1992-01-01 • USA
Syndros approved by the FDA
2016-01-01 • USA
FDA gave green light for Geron clinical trial.
2009-01-01 • US
FDA accepted GW Pharmaceuticals’ New Drug Application (NDA) for the cannabis-derived drug Epidiolex.
2017-10-01 • USA
FDA published industry guidance on botanical drug development.
2016-12-01 • USA
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein event